MoonLake Immunotherapeutics (MLTX) Short term Debt (2021)
MoonLake Immunotherapeutics (MLTX) posted quarterly Short term Debt of $15.0 million for Q4 2021.
MoonLake Immunotherapeutics (MLTX) Short term Debt (2021) Analysis & Trends
MoonLake Immunotherapeutics' Short term Debt history runs 1 years deep, the most recent figure standing at $15.0 million for Q4 2021.
- In Q4 2021, Short term Debt changed N/A year-over-year to $15.0 million; the TTM figure through Dec 2021 stood at $15.0 million (changed N/A YoY), while the FY2021 annual figure was $15.0 million, changed N/A from the prior year.
- Short term Debt for Q4 2021 stood at $15.0 million.
- The five-year high for Short term Debt was $15.0 million in Q4 2021, with the low at $15.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 15.00 Mn |